Intellia Therapeutics (NTLA) to Release Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect Intellia Therapeutics to post earnings of ($1.35) per share for the quarter. Investors interested in participating in the company's conference call can do so using this link.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.47) by $0.01. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. The company had revenue of ($1.92) million during the quarter, compared to analysts' expectations of $15.10 million. During the same period last year, the firm posted ($1.40) earnings per share. On average, analysts expect Intellia Therapeutics to post $-6 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Intellia Therapeutics Stock Performance

NTLA traded up $0.33 during trading hours on Friday, reaching $23.60. The company's stock had a trading volume of 1,294,870 shares, compared to its average volume of 1,480,086. The company's 50-day moving average is $26.11 and its 200-day moving average is $27.35. Intellia Therapeutics has a 52 week low of $19.37 and a 52 week high of $47.48. The firm has a market cap of $2.28 billion, a PE ratio of -4.30 and a beta of 1.85.

Analysts Set New Price Targets

A number of analysts have recently issued reports on NTLA shares. Wedbush restated a "neutral" rating and set a $29.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, April 23rd. The Goldman Sachs Group lowered Intellia Therapeutics from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $136.00 to $32.00 in a research note on Friday, February 23rd. Canaccord Genuity Group lifted their price target on Intellia Therapeutics from $72.00 to $73.00 and gave the stock a "buy" rating in a report on Friday, February 23rd. Finally, Wolfe Research initiated coverage on shares of Intellia Therapeutics in a research note on Thursday, February 15th. They issued a "peer perform" rating on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $67.00.

Insider Activity

In other Intellia Therapeutics news, EVP James Basta sold 2,297 shares of Intellia Therapeutics stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $32.99, for a total value of $75,778.03. Following the transaction, the executive vice president now owns 81,571 shares in the company, valued at $2,691,027.29. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.00% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.